How Can We Get Close to Zero? The Potential Contribution of Biomedical Prevention and the Investment Framework towards an Effective Response to HIV
Author(s)
Type
Journal Article
Abstract
Background: In 2011 an Investment Framework was proposed that described how the scale-up of key HIV interventions
could dramatically reduce new HIV infections and deaths in low and middle income countries by 2015. This framework
included ambitious coverage goals for prevention and treatment services resulting in a reduction of new HIV infections by
more than half. However, it also estimated a leveling in the number of new infections at about 1 million annually after 2015.
Methods: We modeled how the response to AIDS can be further expanded by scaling up antiretroviral treatment (ART)
within the framework provided by the 2013 WHO treatment guidelines. We further explored the potential contributions of
new prevention technologies: ‘Test and Treat’, pre-exposure prophylaxis and an HIV vaccine.
Findings: Immediate aggressive scale up of existing approaches including the 2013 WHO guidelines could reduce new
infections by 80%. A ‘Test and Treat’ approach could further reduce new infections. This could be further enhanced by a
future highly effective pre-exposure prophylaxis and an HIV vaccine, so that a combination of all four approaches could
reduce new infections to as low as 80,000 per year by 2050 and annual AIDS deaths to 260,000.
Interpretation: In a set of ambitious scenarios, we find that immediate implementation of the 2013 WHO antiretroviral
therapy guidelines could reduce new HIV infections by 80%. Further reductions may be achieved by moving to a ‘Test and
Treat’ approach, and eventually by adding a highly effective pre-exposure prophylaxis and an HIV vaccine, if they become
available.
could dramatically reduce new HIV infections and deaths in low and middle income countries by 2015. This framework
included ambitious coverage goals for prevention and treatment services resulting in a reduction of new HIV infections by
more than half. However, it also estimated a leveling in the number of new infections at about 1 million annually after 2015.
Methods: We modeled how the response to AIDS can be further expanded by scaling up antiretroviral treatment (ART)
within the framework provided by the 2013 WHO treatment guidelines. We further explored the potential contributions of
new prevention technologies: ‘Test and Treat’, pre-exposure prophylaxis and an HIV vaccine.
Findings: Immediate aggressive scale up of existing approaches including the 2013 WHO guidelines could reduce new
infections by 80%. A ‘Test and Treat’ approach could further reduce new infections. This could be further enhanced by a
future highly effective pre-exposure prophylaxis and an HIV vaccine, so that a combination of all four approaches could
reduce new infections to as low as 80,000 per year by 2050 and annual AIDS deaths to 260,000.
Interpretation: In a set of ambitious scenarios, we find that immediate implementation of the 2013 WHO antiretroviral
therapy guidelines could reduce new HIV infections by 80%. Further reductions may be achieved by moving to a ‘Test and
Treat’ approach, and eventually by adding a highly effective pre-exposure prophylaxis and an HIV vaccine, if they become
available.
Date Issued
2014-11-05
Date Acceptance
2014-09-23
Citation
PLOS One, 2014, 9 (11)
ISSN
1932-6203
Publisher
Public Library of Science
Journal / Book Title
PLOS One
Volume
9
Issue
11
Copyright Statement
© 2014 Stover et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
License URL
Subjects
Science & Technology
Multidisciplinary Sciences
Science & Technology - Other Topics
PREEXPOSURE PROPHYLAXIS
ANTIRETROVIRAL THERAPY
TRANSMISSION
INFECTION
Publication Status
Published
Article Number
e111956